February 28, 2020
UCB and Daiichi Sankyo have filed an application in Japan for the anti-epilepsy agent Vimpat (lacosamide) seeking an additional indication of adjunctive therapy for tonic-clonic seizures in patients with epilepsy, they said on February 27. The application is based on...read more